Rural Health Information Hub Latest News

Vaccine Shortage Won’t Last Forever

Pfizer and Moderna currently have the market on COVID-19 vaccination, but if all goes well, that won’t be true much longer. COVID-19 has existed for barely more than a year, but 64 vaccines are in clinical development and another 173 in preclinical development worldwide, according to the World Health Organization. Dozens of hopefuls are in clinical trials in the U.S. The two inching closest to the finish line here—by Oxford-AstraZeneca and Johnson & Johnson—although behind original schedules, could win emergency use authorization from the U.S. Food and Drug Administration as soon as this spring. Unfortunately, this week Merck announced it has halted development of two potential vaccines for the coronavirus, citing data that showed a lack of immune response.

CDC Changes COVID-19 Vaccine Guidance to Okay Mixing Pfizer and Moderna Shots

The Centers for Disease Control and Prevention (CDC) quietly changed its guidance on COVID-19 vaccinations, saying it is okay to mix use of Pfizer’s and Moderna vaccine for first and second doses in “exceptional situations” and that it’s also fine to wait up to six weeks to get the second shot of either company’s two-dose immunization. While Pfizer’s and Moderna’s vaccines, which both use messenger RNA technology, were authorized to be given 21 and 28 days apart, respectively, the CDC now says you can receive either shot so long as they are given at least 28 days apart, according to new guidance posted Thursday on its website. Read more.

New MA Bulletin Updates Vaccine Administration Fees

The Pennsylvania Department of Human Services (DHS), Office of Medical Assistance Programs has issued a new bulletin. The purpose of this bulletin is to inform Medical Assistance (MA) providers about updates related to billing and payment for the administration of the novel coronavirus (SARSCoV-2) vaccines, effective Dec. 1, 2020. MAB 01-20-59 advised providers that the administration fee for first and second doses was $10.00. The new administration fee, going back to Dec. 1, 2020, is now $16.94 for the first dose and $28.39 for the second dose. The new fees are based on what Medicare is paying for first and second dose administration and publication of the bulletin indicates DHS received approval from the Centers for Medicare and Medicaid Services (CMS) to pay at Medicare rates. DHS will also pay FQHCs/RHCs for COVID-19 vaccination not affiliated with an FQHC/RHC encounter at Medicare rates, but has not yet published the MA Bulletin affirming this.

Biden Administration Tells Governors PHE to Extend through 2021

The Biden Administration sent a letter to the nation’s Governors signaling its intent to renew the COVID-19 Public Health Emergency (PHE) throughout 2021. Further, the letter indicates that the U.S. Department of Health and Human Services will provide states with 60 days’ notice prior to terminating the PHE or allowing it to expire. Statute requires the PHE to be renewed every 90 days.

NIH Assessment of COVID-19 Vaccine Hesitancy

The National Institutes of Health (NIH) published results of a study to determine what Americans think about getting immunized with the COVID-19 vaccine.  Of a group of 1,878 participants, the greatest reluctance to get a vaccine was found among African-Americans (34%), Hispanics (29%), rural dwellers (29%), and those who had children at home (25%).